BioSpace News Archive

Data from the PRECISE-TAVI study, presented at the PCR Valves 2022 convention in London shows that Transcatheter Aortic Valve Implantation (TAVI) procedures planned by means of FEops HEARTguideTM result in an important change of pre-procedural decision making of the heart team, associated with favorable clinical outcomes.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the management team will present at the 34th Annual Piper Sandler Healthcare Conference at 1:50 p.m. ET on Thursday, December 1, 2022, in New York City as well as host one-on-one meetings throughout the day.

Cubresa Inc., a world leader in brain imaging, is announcing two 2 appointments to its board of directors, Mr. Ryan Klassen, and Ms. Trudy Martens.

Thryv Therapeutics Inc. is pleased to announce the appointment of Melissa Koomey to its Board of Directors.

Sherlock Biosciences today announced that it has received additional funding from the Bill & Melinda Gates Foundation to advance its rapid, instrument-free molecular diagnostic testing platform.

Viatris Inc. announced that it has closed its transaction with Biocon Biologics Limited, creating what Viatris expects to be a unique fully vertically integrated global biosimilars leader.

BigHat Biosciences, Inc. today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease.

Eikonoklastes Therapeutics and Forge Biologics today announced a manufacturing partnership that will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis (ALS).

Agilent Technologies Inc. announced the deployment of the next generation of alarm resolution technology for checkpoints throughout London Heathrow airport, delivering advanced security and efficiency.